==== Front Dis Markers Dis Markers DM Disease Markers 0278-0240 1875-8630 Hindawi 10.1155/2020/8854717 Research Article Vitamin D Deficiency May Not Be an Independent Risk Factor for Peripheral Arterial Disease in Middle-Aged and Elderly Patients with Type 2 Diabetes in China https://orcid.org/0000-0001-8454-0802Wang Yan Feng Tongbao Zhou Hongxing Lu Kefeng Bai Yang https://orcid.org/0000-0002-7098-9657Zhang Ping czeyzp@sina.com Department of Clinical Laboratory, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou, China Academic Editor: Heng Zhou 2020 25 11 2020 2020 885471722 9 2020 22 10 2020 29 10 2020 Copyright © 2020 Yan Wang et al.2020This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Background Vitamin D deficiency can lead to the increased severity and prevalence of metabolic disorders. However, the relationship between levels of 25-hydroxyvitamin D (25(OH)D) and peripheral arterial disease (PAD) is controversial. Therefore, the purpose of our study was to explore the relationship between 25(OH)D levels and PAD in middle-aged and elderly type 2 diabetes mellitus (T2DM) patients in China. Methods In this study, a total of 183 patients with T2DM were enrolled and categorized into groups with or without PAD. Clinical and biochemical parameters were assessed, and a Pearson analysis was used to identify a possible association between levels of 25(OH)D and glycated hemoglobin (HbA1c). Some biochemical parameters were also assessed in the T2DM patients with PAD according to vitamin D status. Interactions were also explored among HbA1c control, 25(OH)D levels, and PAD. The possible risk factors for PAD were measured by multivariable logistic regression analyses. Results Firstly, the parameters including age, HbA1c, and disease duration between T2DM and T2DM+PAD groups showed significantly different. In addition, the frequency of smoking in the group of T2DM patients was significantly less than that in the T2DM patients with the PAD group, while the frequency of well-controlled HbA1c in the patients with T2DM was significantly higher. There is a trend that the levels of 25(OH)D and HbA1c are correlated, but no interactions among vitamin D deficiency, HbA1c control, and PAD were found. However, HbA1c significantly differed between groups with vitamin D deficiency and insufficiency in the T2DM patients with PAD. According to the multivariate logistic regression analyses, the PAD risk factors of T2DM patients were family history of diabetes, smoking, age, disease duration, HbA1c, and LDL. Conclusions The findings demonstrate that the deficiency of vitamin D level is not related to PAD, but HbA1c may be linked to the presence of PAD in middle-aged and elderly patients with T2DM in China. National Natural Science Foundation of China81701516Young Scientists Foundation of ChangzhouQN201933 ==== Body 1. Introduction Peripheral arterial disease (PAD), a prevalent diabetic complication, although most PAD patients are asymptomatic, also can raise the risk of morbidity of these patients [1]. PAD can reduce blood flow and obstruct arteries due to atherosclerotic plaques [2], which can cause an increased risk of limb and cardiovascular disease [3, 4]. A review showed a higher incidence of PAD in people over the age of 65 years [5]. Therefore, the early designation, assessment, and treatment of T2DM patients with higher risks of PAD are critical and warranted. It is extremely clear that vitamin D exerts a significant effect on the processes of bone mineral metabolism and maintenance of calcium homeostasis. Recent evidence has also shown the vascular endothelial damage [6] and the prevalence of diabetes [7] caused by the deficiency of vitamin D. Vitamin D deficiency is a common condition in the world. Therefore, multiple studies have uncovered the relationship between levels of 25-hydroxyvitamin D (25(OH)D) and PAD; however, the results are inconsistent. While some studies have demonstrated that deficiency of vitamin D and PAD showed a correlation [8, 9], another found no association between levels of 25(OH)D and PAD popularity and severity [10]. To date, evidence is limited on indicating the relationships between 25(OH)D levels and PAD in middle-aged and elderly patients with T2DM in China. Therefore, the objective of this study was to uncover the possible underlying effects of 25(OH)D on PAD in middle-aged and elderly patients with T2DM in China. 2. Materials and Methods 2.1. Patients and Samples 183 T2DM-diagnosed patients were collected in our study from the Department of Endocrinology at Changzhou No.2 People's Hospital. According to the World Health Organization diagnostic criteria, T2DM was diagnosed if the glucose value of a fasting plasma is ≥7.0 mmol/L or a 2 h value during an oral test of glucose tolerance is ≥11.1 mmol/L [11]. All the 183 T2DM patients, 108 males and 75 females, were separated into T2DM with (T2DM+PAD) or without PAD (T2DM) group. Patients with hepatic disease, acute illnesses, chronic kidney disease, cancer present, a disease affecting vitamin D metabolism, or type 1 diabetes mellitus were excluded. In addition, those with drugs interfering with vitamin D status or calcium level, or with glucocorticoids or calcitonin in the past 3 months, were not included. Patients aged <40 or >65 years were also excluded. Relevant parameters including age, sex, disease duration, hypertension, smoking habits, and family history of diabetes were collected by face-to-face interviews. Hypertension was diagnosed with blood pressure (BP) ≥ 140/90 mmHg or administration of antihypertensive drugs. Patients were classified as smokers or nonsmokers, with subjects who had never had cigarettes in their life defined as nonsmokers. Smokers were defined as people with the habit of smoking including those who quit forever. Body height (in meters, m) and weight (in kilograms, kg) were checked and documented, and the calculation of weight (kg) divided by the square of body height (m) was used as an assessment of corrected weight body mass index (BMI). The season when blood samples were obtained was recorded for all patients. As this study was conducted in Changzhou (latitude 31.78°S), a city in the south of China, June to October was defined as the summer-autumn season, and November to May of the following year was defined as the winter-spring season. All patients had free exposure to sunlight. This study was carried out with the consent of the Committee of Ethics at Changzhou No.2 People's Hospital. Each participant was notified and enrolled in the study with written consent forms. 2.2. Diagnosis of Peripheral Arterial Disease (PAD) As a measurement to diagnose PAD, the ankle-brachial blood pressure index (ABI) was calculated as the ankle-to-arm systolic blood pressure ratio [12]. The blood pressures of both arm and ankle were tested using a device equipped with ABI output (VaSera VS-1000, Japan). A value of ABI < 0.9 indicated the diagnosis of PAD [13, 14]. Patients were also classified as having PAD during angioplasty examination, as in our previous study [15]. 2.3. Biochemical Measurements All the fasting blood samples of enrolled patients were collected the next morning and processed within 1 h to test the biochemical variables. Triglycerides (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol (TC), lipoprotein B (ApoB), lipoprotein A1 (ApoA1), lipoprotein A (LPA), serum creatinine, phosphate, calcium, and uric acid were tested using automatic analyzers (Cobas 8000, Germany). Parathormone (PTH) levels were measured by radioimmunoassay (Cobas e602, Germany). The high-performance liquid chromatography (HPLC) method was used for the determination of glycated hemoglobin (HbA1c) values (Tosoh G8, Japan). Glycemic control values were classified as poorly controlled (HbA1c ≥ 7%) and well controlled (HbA1c < 7%) [16]. The levels of serum 25(OH)D were detected by an autoanalyzer (Cobas 8000, Germany) with an electrochemiluminescence immunoassay. In this study, the 25(OH)D value < 50 nmol/L was regarded as deficiency of vitamin D, vitamin D sufficiency was defined as 25(OH)D > 75 nmol/L, and 25(OH)D levels between 50 and 75 nmol/L were considered as vitamin D insufficiency [17, 18]. 2.4. Statistical Analysis Data collected and analyzed in this study were presented as the mean ± SD. All analyses to measure the statistical significance were carried out using SPSS 16.0 (SPSS Inc., Chicago, USA). Differences of clinical parameters including age, BMI, disease duration, HbA1c, TG, HDL, TC, LDL, ApoA1, ApoB, LPA, serum calcium, serum phosphate, serum creatinine, serum uric acid, 25(OH)D, and PTH values between the two groups were measured by independent sample Student's t tests. And analyses of classified data such as hypertension, sex, smoking habits, and family history of diabetes were conducted by a chi-squared test or Fisher's exact test. The variables among the three different-levels-of-25(OH)D groups in the T2DM patients with PAD were compared by an analysis of variance (ANOVA). LSD-t is used when the variances between groups are assumed. An analysis of multivariate logistic regression was performed for assessments of the PAD risk factors, and the value was represented as an adjusted odds ratio (OR) with 95% confidence intervals (CI). The value of P < 0.05 was of statistical significance. 3. Results 3.1. Clinical Characteristics of the Patients Enrolled in the Study The clinical data for the T2DM patients are displayed in Table 1. Of the T2DM patients with PAD, 74 (63.2%) were male, 48 (41.0%) had a diabetic family history, and 53 (45.3%) had hypertension. Differences between the two groups for HbA1c, smoking habits, age, and disease duration were measured significantly. In addition, patients with well-controlled HbA1c showed a higher proportion in the T2DM group (P ≤ 0.001). No significant difference was found in the serum 25(OH)D levels in T2DM patients with or without PAD (54.46 ± 11.87 nmol/L vs. 50.84 ± 12.31 nmol/L, P = 0.055). The frequency of vitamin D deficiency also showed no difference (23, 34.8% vs. 58, 49.6%, P = 0.054). No differences in other clinical data between the two groups showed statistically significant. 3.2. Correlation between Serum 25(OH)D Levels and HbA1c The dot chart displayed in Figure 1 shows there is a trend that the levels of 25(OH)D and HbA1c are correlated, with a correlation coefficient of −0.209, despite P < 0.05. 3.3. Association of Levels of 25(OH)D with Lipid Profiles and HbA1c The association between 25(OH)D level, the lipid profiles, and HbA1c in the T2MD+PAD group is displayed in Table 2. Compared to the vitamin D sufficiency group, the levels of TC and LDL in the group of vitamin D deficiency were higher and HDL levels were lower, but no significant differences were found. However, the difference of HbA1c levels between the two groups of vitamin D deficiency and insufficiency was significant. 3.4. Serum 25(OH)D Levels, HbA1c, and Their Interaction with PAD Figure 2 displays a stacked bar chart showing no significant difference between three groups based on the levels of vitamin D in glycemic well-controlled patients. Additionally, the proportion of patients with PAD in patients with sufficiency of vitamin D was lower among the three groups, but the difference was not statistically significant. Figure 3 is also a stacked bar chart showing no significant difference when comparing the three groups in the poorly controlled glycemia patients. The proportion of PAD patients was similar between those three groups. 3.5. Association between Clinical Variables with the Risk of PAD The clinical variables associated with PAD were analyzed by an analysis of multivariate logistic regression. The PAD presence (1 = PAD, 0 = non‐PAD) was a dependent variable considering all subjects as a whole. Sex (1 = male, 2 = female), diabetic family history (1 = yes, 0 = no), smoking (1 = smoker, 0 = nonsmoker), hypertension (1 = hypertension, 0 = nonhypertension), BMI, disease duration, HbA1c, 25(OH)D, TC, HDL, TG, LDL, ApoB, ApoA1, and LPA were regarded as covariates. The results displayed in Table 3 show that age (P = 0.011), diabetic family history (P = 0.043), disease duration (P = 0.001), smoking (P = 0.006), LDL (P = 0.031), and HbA1c (P = 0.016) were significant factors for prediction of the PAD presence in T2DM patients. Multivariate logistic regression further verified that 25(OH)D was irrelevant to PAD in T2DM patients (P = 0.116). 4. Discussion Our results indicate that deficiency of vitamin D was not correlated to PAD. However, HbA1c may be correlated with the appearance of PAD in middle-aged and elderly T2DM patients in China. In our study, we refer PAD to limb condition with arterial occlusion [19]. The occurrence and progression of PAD are linked to many diseases or factors such as ethnicity, abnormal lipid metabolism, and diabetes [20]. Besides the established risk factors including age [21], smoking [20], and dyslipidemia [22] for PAD, HbA1c was found likely to be a PAD independent risk factor, which is consistent with our previous study [15]. HbA1c, the important factor of detecting glycemic control, is produced by the nonenzymatic glycation reaction in the blood based on hemoglobin and glucose. Additionally, glucose, protein, and lipids under the reactions of nonenzymatic glycosylation can produce advanced glycation end products (AGEs) [23]. Thus, HbA1c shows a significant association with AGEs, which can accelerate the progression of PAD in several ways [24–27]. A recent Chinese study has indicated that the deficiency of vitamin D is associated with PAD in T2DM patients after adjustment for various risk factors [9]. Another study has also confirmed that deficiency of vitamin D, as an independent factor, can increase the risks of PAD incidence [28]. One possible explanation may be that a normal vitamin D level can prevent foam cell formation, while vitamin D deficiency may promote the progression of atherosclerosis [29]. In this study, however, we found no association between the levels of 25(OH)D and PAD in middle-aged and elderly T2DM patients, possibly because the number of PAD patients is relatively small. A second possible reason may be due to age differences, as our patients were younger (limited to middle-aged and elderly patients) than the populations in the other studies. The vitamin D receptor expression level descends linearly with age [30], suggesting that extremely high levels of 25(OH)D would probably be a necessity to the elderly to prevent atherosclerotic processes [31]. In addition, our diagnostic criterion for PAD differed from the other studies, as we also included patients identified during angioplasty examinations. In our study, there is a trend that the levels of serum 25(OH)D are correlated with HbA1c, which significantly differed between patients with insufficient and deficient vitamin D in T2DM patients with PAD. This suggests that active glucose control not only is a benefit to the PAD prevention and therapy but also may be beneficial for the increase of 25(OH)D. In terms of limitations of considering only Chinese people in the present study, the results generalizing to other ethnic people can probably be not appropriate due to racial different levels of 25(OH)D [32]. In addition, data on drug therapy were not collected and analyzed which is warranted to be done in the future in-depth studies. 5. Conclusions In conclusion, findings in this study demonstrated that deficiency of vitamin D was not linked to PAD, but HbA1c may be correlated to the occurrence of PAD in middle-aged and elderly patients with T2DM in China. Furthermore, the prevention of PAD incidence and progression should be studied and performed in T2DM patients with clinical characteristics with high risks. Acknowledgments This study was subsidized by the Young Scientists Foundation of Changzhou (No. QN201933) and the Young Scientists Foundation of National Natural Science of China (No. 81701516). We thank all patients enrolled in this study whose blood was collected and analyzed for data analyses. We also thank Mrs. Qian for her help on statistical analyses and Kirsten Jan for the language help. Data Availability Data are not available. All the findings of this study are carried out by analyzing the datasets that appeared in this manuscript. Conflicts of Interest No conflict of interest in this paper was declared. Authors' Contributions YW performed data analyses and manuscript preparation and completion. PZ completed the study design. TF analyzed the data. HZ, KL, and YB collected blood samples and clinical data. All the authors contributing to this study read the final manuscript and approved its publication. Figure 1 The relationship between serum levels of vitamin D and glycated hemoglobin (HbA1c) in all analyzed patients. Figure 2 Distribution of peripheral arterial disease (PAD) in different vitamin D status groups of patients with well-controlled glycemia. HbA1c: glycated hemoglobin; well-controlled HbA1c defined as HbA1c < 7%. The levels of vitamin D was represented as 25-hydroxyvitamin-D (25(OH)D) levels: deficiency, 25(OH)D value < 50 nmol/L; insufficiency, 25(OH)D value ≥ 50 and <75 nmol/L; sufficiency, 25(OH)D value ≥ 75 nmol/L. Figure 3 Distribution of peripheral arterial disease (PAD) in glycemic poorly controlled patients and vitamin D status of deficiency, insufficiency, or sufficiency. HbA1c: glycated hemoglobin; well-controlled HbA1c defined as HbA1c < 7%. Table 1 Clinical and biochemical characteristics of type 2 diabetes mellitus (T2DM) patients with and without peripheral arterial disease (PAD). Parameters All participants (n = 183) T2DM (n = 66) T2DM+PAD (n = 117) P Age (years) 55.42 ± 7.20 53.20 ± 7.23 56.68 ± 6.91 0.002∗ Male, n (%) 108 (59.0%) 34 (51.5%) 74 (63.2%) 0.121 Disease duration (years) 6.90 ± 6.13 4.47 ± 4.70 8.27 ± 6.43 0.001∗ Hypertension, n (%) 79 (43.2%) 26 (39.4%) 53 (45.3%) 0.439 Smoking, n (%) 83 (45.4%) 22 (33.3%) 61 (52.1%) 0.014∗ Diabetes, n (%) 82 (44.8%) 34 (51.5%) 48 (41.0%) 0.171 BMI (kg/m2) 24.95 ± 3.12 24.96 ± 3.16 24.95 ± 3.11 0.971 TG (mmol/L) 1.85 ± 0.99 1.98 ± 1.09 1.77 ± 0.93 0.181 LDL (mmol/L) 2.51 ± 0.72 2.39 ± 0.73 2.58 ± 0.71 0.096 HDL (mmol/L) 1.10 ± 0.31 1.12 ± 0.38 1.10 ± 0.26 0.702 TC (mmol/L) 4.60 ± 0.87 4.53 ± 0.83 4.64 ± 0.89 0.432 ApoB (g/L) 1.05 ± 0.76 0.98 ± 0.21 1.09 ± 0.94 0.348 ApoA1 (g/L) 1.24 ± 0.21 1.25 ± 0.21 1.23 ± 0.20 0.639 LPA (g/L) 0.14 ± 0.15 0.13 ± 0.11 0.15 ± 0.16 0.244 HbA1c (%) 8.54 ± 1.93 8.16 ± 1.64 8.76 ± 2.06 0.034∗ 25(OH)D (nmol/L) 52.15 ± 12.24 54.46 ± 11.87 50.84 ± 12.31 0.055 Creatinine (μmol/L) 63.17 ± 14.43 62.04 ± 15.15 63.81 ± 14.03 0.426 Phosphate (mmol/L) 1.15 ± 0.17 1.18 ± 0.16 1.13 ± 0.18 0.103 Calcium (mmol/L) 2.24 ± 0.10 2.24 ± 0.09 2.24 ± 0.10 0.999 Serum uric acid (μmol/L) 299.70 ± 71.18 304.73 ± 67.61 296.50 ± 73.25 0.475 PTH (ng/L) 40.03 ± 12.75 38.75 ± 12.69 40.75 ± 12.78 0.308 HbA1c controlled, n (%) 0.001∗  Yes 40 (21.9%) 25 (37.9%) 15 (12.8%)  No 143 (78.1%) 41 (62.1%) 102 (87.2%) Vitamin D deficiency, n (%) 0.054  Yes 81 (44.3%) 23 (34.8%) 58 (49.6%)  No 102 (55.7%) 43 (65.2%) 59 (50.4%) Season, n (%) 0.678  Spring-winter 98 (53.6%) 34 (51.5%) 64 (54.7%)  Summer-autumn 85 (46.4%) 32 (48.5%) 53 (45.3%) ∗ P < 0.05. BMI: body mass index; TG: triglycerides; LDL: low-density lipoprotein; HDL: high-density lipoprotein; TC: total cholesterol; ApoB: lipoprotein B; ApoA1: lipoprotein A1; LPA: lipoprotein A; HbA1c: glycated hemoglobin; 25(OH)D: 25-hydroxyvitamin-D; PTH: parathormone; vitamin D deficiency: 25(OH)D < 50 nmol/L; HbA1c controlled: HbA1c < 7%. Table 2 Biochemical parameters according to vitamin D status in T2DM patients with peripheral arterial disease. Group Number TC HbA1c LDL HDL A 58 4.71 ± 0.90 9.21 ± 2.10 2.64 ± 0.75 1.11 ± 0.27 B 54 4.58 ± 0.91 8.35 ± 2.00 2.53 ± 0.69 1.08 ± 0.25 C 5 4.50 ± 0.45 7.86 ± 0.85 2.39 ± 0.27 1.18 ± 0.18 LSD-t, P A vs. C 0.627 0.155 0.444 0.577 B vs. C 0.852 0.599 0.681 0.438 A vs. B 0.462 0.028∗ 0.384 0.586 ∗ P < 0.05. A: deficiency of vitamin D, 25(OH)D level < 50 nmol/L; B: insufficiency of vitamin D, 25(OH)D level < 75 and ≥50 nmol/L; C: sufficiency of vitamin D, 25(OH)D level ≥ 75 nmol/L; 25(OH)D: 25-hydroxyvitamin-D; TC: total cholesterol; HbA1c: glycated hemoglobin; LDL: low-density lipoprotein; HDL: high-density lipoprotein. Table 3 Analyses of multivariate logistic regression for peripheral arterial disease-associated clinical factors in all patients. Parameters OR 95% CI P Age 1.076 1.017–1.138 0.011∗ Sex 1.011 0.369–2.776 0.982 Diabetic family history 0.475 0.231–0.977 0.043∗ Smoking 2.844 1.349–5.996 0.006∗ Disease duration 1.137 1.056–1.225 0.001∗ Hypertension 0.880 0.400–1.939 0.752 BMI 1.008 0.874–1.162 0.914 TG 0.763 0.481–1.211 0.251 LDL 1.709 1.052–2.778 0.031∗ HDL 0.795 0.143–4.415 0.793 TC 1.123 0.468–2.695 0.796 ApoB 1.290 0.488–3.411 0.608 ApoA1 0.737 0.054–10.053 0.819 LPA 1.036 0.067–12.029 0.980 HbA1c 1.282 1.047–1.570 0.016∗ 25(OH)D 0.975 0.944–1.006 0.116 ∗ P < 0.05. A multivariate logistic regression analysis was performed to analyze the data. OR: odds ratio; CI: confidence interval; BMI: body mass index; TG: triglycerides; LDL: low-density lipoprotein; HDL: high-density lipoprotein; TC: total cholesterol; ApoB: lipoprotein B; ApoA1: lipoprotein A1; LPA: lipoprotein A; HbA1c: glycated hemoglobin; 25(OH)D: 25-hydroxyvitamin-D. ==== Refs 1 Jude E. B. Eleftheriadou I. Tentolouris N. Peripheral arterial disease in diabetes--a review Diabetic Medicine 2010 27 1 4 14 10.1111/j.1464-5491.2009.02866.x 2-s2.0-73949152177 20121883 2 Hamburg N. M. Creager M. A. Pathophysiology of intermittent claudication in peripheral artery disease Circulation Journal 2017 81 3 281 289 10.1253/circj.CJ-16-1286 2-s2.0-85013923210 28123169 3 Ankle Brachial Index Collaboration Fowkes F. G. R. Murray G. D. Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis JAMA 2008 300 197 208 10.1001/jama.300.2.197 2-s2.0-47049084052 18612117 4 Bhatt D. L. Steg P. G. Ohman E. M. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis JAMA 2006 295 2 180 189 10.1001/jama.295.2.180 2-s2.0-30444453441 16403930 5 Norgren L. Hiatt W. R. Dormandy J. A. Nehler M. R. Harris K. A. Fowkes F. G. R. Inter-society consensus for the management of peripheral arterial disease (TASC II) European Journal of Vascular and Endovascular Surgery 2007 33 1 S1 75 10.1016/j.ejvs.2006.09.024 2-s2.0-33845241195 17140820 6 Bozic M. Álvarez Á. de Pablo C. Impaired vitamin D signaling in endothelial cell leads to an enhanced leukocyte-endothelium interplay: implications for atherosclerosis development PLoS One 2015 10 8, article e0136863 10.1371/journal.pone.0136863 2-s2.0-84943339725 26322890 7 Takiishi T. Gysemans C. Bouillon R. Mathieu C. Vitamin D and diabetes Rheumatic Diseases Clinics of North America 2012 38 1 179 206 10.1016/j.rdc.2012.03.015 2-s2.0-84860007403 22525851 8 Melamed M. L. Muntner P. Michos E. D. Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 6 1179 1185 10.1161/ATVBAHA.108.165886 2-s2.0-44849087389 9 Yuan J. Jia P. Hua L. Xin Z. Yang J. K. Vitamin D deficiency is associated with risk of developing peripheral arterial disease in type 2 diabetic patients BMC Cardiovascular Disorders 2019 19 1 p. 145 10.1186/s12872-019-1125-0 2-s2.0-85067418481 31208330 10 Liew J. Y. Sasha S. R. Ngu P. J. Circulating vitamin D levels are associated with the presence and severity of coronary artery disease but not peripheral arterial disease in patients undergoing coronary angiography Nutrition, Metabolism, and Cardiovascular Diseases 2015 25 3 274 279 10.1016/j.numecd.2014.12.005 2-s2.0-84933670505 11 Puavilai G. Chanprasertyotin S. Sriphrapradaeng A. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the expert committee on the diagnosis and classification of diabetes mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization Diabetes Research and Clinical Practice 1999 44 1 21 26 10.1016/s0168-8227(99)00008-x 2-s2.0-0032832015 10414936 12 European Stroke Organisation Tendera M. Aboyans V. ESC guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the task force on the diagnosis and treatment of peripheral artery diseases of the European Society of Cardiology (ESC) European Heart Journal 2011 32 2851 2906 10.1093/eurheartj/ehr211 2-s2.0-81855199782 21873417 13 Aboyans V. Criqui M. H. Abraham P. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association Circulation 2012 126 24 2890 2909 10.1161/CIR.0b013e318276fbcb 2-s2.0-84870919920 23159553 14 Fowkes F. G. R. Rudan D. Rudan I. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis Lancet 2013 382 9901 1329 1340 10.1016/S0140-6736(13)61249-0 2-s2.0-84885871253 23915883 15 Hu Y. Ling T. Yu M. Apolipoprotein E gene polymorphism, glycated hemoglobin, and peripheral arterial disease risk in Chinese type 2 diabetic patients Disease Markers 2020 2020 6 6040525 10.1155/2020/6040525 32211081 16 Long M. Wang C. Liu D. Glycated hemoglobin A1c and vitamin D and their association with diabetic retinopathy severity Nutrition & Diabetes 2017 7 6, article e281 10.1038/nutd.2017.30 2-s2.0-85043723306 28604686 17 Holick M. F. Vitamin D Deficiency The New England Journal of Medicine 2007 357 3 266 281 10.1056/NEJMra070553 2-s2.0-34447514029 17634462 18 Holick M. F. Binkley N. C. Bischoff-Ferrari H. A. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline The Journal of Clinical Endocrinology and Metabolism 2011 96 7 1911 1930 10.1210/jc.2011-0385 2-s2.0-79960104336 21646368 19 Creager M. A. White C. J. Hiatt W. R. Atherosclerotic peripheral vascular disease symposium II: executive summary Circulation 2008 118 25 2811 2825 10.1161/CIRCULATIONAHA.108.191170 2-s2.0-58249140609 19106402 20 Fowkes F. G. R. Aboyans V. Fowkes F. J. I. McDermott M. M. Sampson U. K. A. Criqui M. H. Peripheral artery disease: epidemiology and global perspectives Nature Reviews Cardiology 2017 14 3 156 170 10.1038/nrcardio.2016.179 2-s2.0-84995810879 27853158 21 Krishna S. M. Moxon J. V. Golledge J. A review of the pathophysiology and potential biomarkers for peripheral artery disease International Journal of Molecular Sciences 2015 16 12 11294 11322 10.3390/ijms160511294 2-s2.0-84930643414 25993296 22 Aday A. W. Everett B. M. Dyslipidemia profiles in patients with peripheral artery disease Current Cardiology Reports 2019 21 6 p. 42 10.1007/s11886-019-1129-5 2-s2.0-85064903765 31011836 23 Vistoli G. De Maddis D. Cipak A. Zarkovic N. Carini M. Aldini G. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation Free Radical Research 2013 47 Supplement 1 3 27 10.3109/10715762.2013.815348 2-s2.0-84881240163 23767955 24 Soro-Paavonen A. Zhang W. Z. Venardos K. Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase Journal of Hypertension 2010 28 4 780 788 10.1097/HJH.0b013e328335043e 2-s2.0-77956819409 20186099 25 Yamagishi S.-i. Ueda S. Matsui T. Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties Protein and Peptide Letters 2007 14 8 832 835 10.2174/092986607781483705 2-s2.0-34548679360 17979828 26 Yamagishi S. Matsui T. Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy-friend or foe? Pharmacological Research 2011 64 3 187 194 10.1016/j.phrs.2011.05.009 2-s2.0-79960014508 21635951 27 Wang Z. Q. Jing L. L. Yan J. C. Role of AGEs in the progression and regression of atherosclerotic plaques Glycoconjugate Journal 2018 35 5 443 450 10.1007/s10719-018-9831-x 2-s2.0-85049657687 29987432 28 van de Luijtgaarden K. M. Voûte M. T. Hoeks S. E. Vitamin D deficiency may be an independent risk factor for arterial disease European Journal of Vascular and Endovascular Surgery 2012 44 3 301 306 10.1016/j.ejvs.2012.06.017 2-s2.0-84865480067 22841360 29 Oh J. Weng S. Felton S. K. 1,25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus Circulation 2009 120 8 687 698 10.1161/CIRCULATIONAHA.109.856070 2-s2.0-69549116323 19667238 30 Baker M. R. Peacock M. Nordin B. E. C. The decline in vitamin D status with age Age and Ageing 1980 9 4 249 252 10.1093/ageing/9.4.249 2-s2.0-0019220115 6971044 31 Veronese N. Rui M. D. Bolzetta F. Serum 25-hydroxyvitamin D and the incidence of peripheral artery disease in the elderly: the Pro.V.A study Journal of Atherosclerosis and Thrombosis 2015 22 7 726 734 10.5551/jat.28134 2-s2.0-84937919113 25739824 32 Hilger J. Friedel A. Herr R. A systematic review of vitamin D status in populations worldwide The British Journal of Nutrition 2014 111 1 23 45 10.1017/S0007114513001840 2-s2.0-84891406297 23930771